StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
6-factor scoring with sector-relative rank. Updated daily.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $5.12 | $5.31 | +3.71% | 0.3M |
| 05-12 | $5.27 | $4.93 | -6.45% | 0.3M |
| 05-13 | $4.85 | $4.90 | +1.03% | 0.1M |
| 05-14 | $4.94 | $5.20 | +5.26% | 0.4M |
| 05-15 | $5.17 | $4.98 | -3.68% | 0.2M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
No sell-side coverage available for SGHT.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Fundamentals not available for SGHT.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $19.70M | $77.36M | $56.98M | $37.07M |
Operating Income | $-12.41M | $-37.10M | $-33.43M | $-25.53M |
Net Income | $-12.98M | $-38.43M | $-34.26M | $-26.09M |
EPS (Diluted) | $-0.24 | $-0.74 | $-0.66 | $-0.51 |
Total Assets | $109.70M | $115.30M | $116.26M | $121.97M |
Total Liabilities | $55.80M | $51.36M | $51.97M | $51.96M |
Cash & Equivalents | $84.96M | $91.97M | $92.37M | $101.50M |
Free Cash Flow OCF − CapEx | $-7.09M | $-29.92M | $-28.25M | $-19.36M |
Shares Outstanding | 54.03M | 53.49M | 52.47M | 52.03M |
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.